[{"id":"a4f66c58-b801-4e04-8f10-03d510d61f4a","acronym":"MK-4166-001","url":"https://clinicaltrials.gov/study/NCT02132754","created_at":"2021-01-18T09:53:38.686Z","updated_at":"2024-07-02T16:36:35.436Z","phase":"Phase 1","brief_title":"Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)","source_id_and_acronym":"NCT02132754 - MK-4166-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TNFA • IL2RA • CD4 • FAS","pipe":"","alterations":" ","tags":["TNFA • IL2RA • CD4 • FAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-4166"],"overall_status":"Completed","enrollment":" Enrollment 116","initiation":"Initiation: 06/27/2014","start_date":" 06/27/2014","primary_txt":" Primary completion: 07/31/2019","primary_completion_date":" 07/31/2019","study_txt":" Completion: 07/31/2019","study_completion_date":" 07/31/2019","last_update_posted":"2021-01-28"}]